SHANGHAI, CHINA, July 31, 2024 - JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, is pleased to announce that Mr. Min Liu has been appointed as Chief Executive Officer of JW Therapeutics with effect from 31 July, 2024. Mr. Liu will also serve as an Executive Director on company’s Board of Directors. Dr. Yiping James Li has resigned from his role as the Chief Executive Officer of the Company to dedicate more time for his family and other personal interests, and he will remain as the interim chairman of the Board to provide support to his successor and facilitate a smooth transition. The Board would like to take this opportunity to express its appreciation to Dr. Li for his valuable contributions to the Company and look forward to his continued support for the Company.
Mr. Min Liu possesses over 25 years of experience in pharmaceutical industry. Prior to joining JW Therapeutics, he served as the chief commercial officer of Innovent Biologics, Inc., where during his tenure he helped build Innovent’s commercial capabilities with a leading competitive commercialization organization in the market. He led the key successful launches of various innovative products, planned and executed the major market access strategy to establish market share leadership, and managed key partnership collaborations and reached major strategic deals. Before that, Mr. Liu served at as a vice president at Roche in the PRC, where he led the development of various business units, including one of the two oncology business units of Roche in the PRC. Earlier in his career, Mr. Liu also held managerial roles in a number of reputable multinational pharmaceutical companies.
After joining JW Therapeutics, Mr. Liu will lead the Company with a focus on innovation, strategic partnership, operational excellence, and creating long-term value for all stakeholders.
Mr. Min Liu, Chief Executive Officer of JW therapeutics, said, “I am very happy to join JW Therapeutics and I am looking forward to working with our team of leading scientists and industry experts, we are committed to further strengthen JW’s leading position in cell therapy industry. Currently, our leading product Carteyva? has been approved in two indications in China. We will work hard to explore the opportunity to bring more indications both in hematology and auto-immune disease area to China market and benefit more patients.”
About Relmacabtagene Autoleucel Injection
Relmacabtagene autoleucel injection (abbreviated as relma-cel, trade name for oncology indications: Carteyva?) is an autologous anti-CD19 CAR-T cell immunotherapy product independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). Being the first product of JW Therapeutics, relma-cel has been approved by the China National Medical Products Administration (NMPA) for two indications, including the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBLC) after two or more lines of systemic therapy, and the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL), making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, priority review and breakthrough therapy designations.
About JW Therapeutics
JW Therapeutics (Stock Code: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, and is committed to becoming an innovation leader in cell immunotherapy. Founded in 2016, JW Therapeutics has built a world-class platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and worldwide, and leading the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit .
Forward-Looking Statements
The forward-looking statements are based on the management's expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website: .